Windsong is excited to announce that it is now offering a new FDA approved treatment for prostate cancer. Xofigo® (Radium 223 dichloride) is a new therapy used to treat prostate cancer that is resistant to other medical and surgical treatments that seek to lower testosterone levels in patients whose disease has spread to the bones.
Patients meeting certain criteria including acceptable white blood cell and platelet counts, along with proven metastatic bone disease, may be eligible for up to 6 monthly infusions of Xofigo treatment. The monthly administration is very simple, and side effects are minimal. Dr. Thomas Summers, president of Windsong said, “We are proud to offer a convenient new site in Williamsville for this treatment, which up until this point was only available at Roswell Park.”
According to the American Cancer Society, prostate cancer is the most common type of cancer found in American men, other than skin cancer. This year alone, nearly 230,000 men will be diagnosed with the cancer and nearly 29,500 will die from the disease in the U.S. If prostate cancer starts to spread to other areas of the body, it most commonly goes to the bones which results in rapid tumor growth. The alpha particle-emitting isotope radium-223, mimics calcium and targets bone metastases. It is reported that patients who receive XOFIGO live longer, and demonstrate a delay in their first bone- related symptom or event.
This cutting edge treatment option is just one more demonstration of Windsong’s commitment to bringing the latest medicines to patients. For more information, please contact Laurie Fuller at
716.631.2500, ext. 2152 or go to xofigo-us.com.